Quest Diagnostics (DGX) Tops Q3 EPS by 19c; Guides Higher
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $235.50 -0.69%
Revenue Growth %: +7.8%
Financial Fact:
Amortization of intangible assets: 18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.8%
Financial Fact:
Amortization of intangible assets: 18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.36, $0.19 better than the analyst estimate of $2.17. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.33 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $9.75-$9.95, versus the consensus of $9.68.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $245 at UBS
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
